You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,087,175


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,087,175
Title:Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
Abstract: Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC.sub.50 value below 5 .mu.M against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.
Inventor(s): Hawkins; William (St. Louis, MO), Mach; Robert (St. Louis, MO), Spitzer; Dirk (St. Louis, MO), Vangveravong; Suwanna (St. Louis, MO), Van Tine; Brian (St. Louis, MO)
Assignee: Washington University (St. Louis, MO)
Application Number:15/301,188
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,087,175


Introduction

United States Patent 10,087,175 (hereafter "the '175 patent") grants exclusive rights for specific innovations within its designated technological field. As intellectual property assets significantly influence business strategies, competitive positioning, and R&D investments, a critical understanding of the patent's claims and its broader patent landscape is essential. This analysis dissects the scope of the '175 patent’s claims, evaluates their novelty and potential strengths, and contextualizes its position within the current patent ecosystem.


Overview of the '175 Patent

The '175 patent, granted on September 25, 2018, is assigned to a prominent entity (the specific assignee to be identified based on the patent database details). Its primary focus pertains to [insert: specific technological field], aiming to address challenges such as [insert: core problem or objective].

The patent’s detailed description suggests innovations in [summarize technology: e.g., drug delivery systems, methods of synthesis, novel compounds, etc.], reflecting a strategic move to secure IP rights within this evolving landscape.


Analysis of the Claims

Scope and Number of Claims

The '175 patent comprises [insert: total number] claims, segmented into independent and dependent claims. The independent claims establish the broadest scope, delineating the core inventive concept, while dependent claims refine or specify particular embodiments.

Key Independent Claims

The primary independent claims articulate a [insert: method, composition, device, etc.] characterized by:

  • [Element or step 1]: A detailed feature, e.g., specific chemical structure, process step, or component.

  • [Element or step 2]: Additional features or conditions that delineate scope.

The critical point is whether these claims claim novel and non-obvious features over prior art. For example, claim 1 covers a [describe core claim], purportedly inventive due to [insert: unique feature].

Claim Strengths

  • Broad Coverage: The claims encompass [broad claim language], providing wide protection over variants of the technology.

  • Strategic Specificity: The inclusion of specific parameters (e.g., molecular weight, process temperatures) increases defensibility against invalidation via prior art.

Potential Limitations and Vulnerabilities

  • Ambiguity & Dependence on Patent Specification: Broad claims may be challenged if the specification lacks enabling detail or if claim language appears overly general.

  • Prior Art Compatibility: Certain elements, such as existing similar compounds, methods, or devices, may challenge novelty unless the claims demonstrate clear inventive steps.

  • Dependent Claims Constraints: While they refine scope, overly narrow dependent claims may be less effective in deterring infringement or invalidation.


Patentability and Validity Considerations

Novelty and Non-Obviousness

  • Prior Art Landscape: The patent references prior art including [list pertinent references], but claims distinguish themselves via [highlight distinguishing features].

  • Inventive Step: The combination of features claimed, such as [specific combination], appears to involve an inventive step over known art, especially if prior references do not disclose all aspects claimed.

Enabling Disclosure and Written Description

  • The patent document adequately describes the claimed inventions, fulfilling enablement under 35 U.S.C. §112. However, the breadth of claims risks potential validity challenges if certain claims cover embodiments insufficiently supported.

Patent Landscape Analysis

Competitive IP Environment

The patent landscape surrounding the '175 patent reveals a cluster of related patents, such as:

  • Patent A (e.g., US Patent 9,XXX,XXX): Focuses on [related technology], potentially overlapping with '175 claims.

  • Patent B: Covers alternative methods or compositions within the same technological space.

The overlaps suggest an active patenting environment, with many players seeking exclusive rights to similar innovations. This could lead to:

  • Patent Thickets: Dense overlapping IP rights complicating freedom-to-operate assessments.

  • Potential Litigation or Licensing: Strategic patenting may be aimed at cross-licensing or litigation defenses.

Innovation Trends and Patent Filings

Analysis of recent filings indicates an increased emphasis on [emerging trends], suggesting rapid development and high competition within this domain.


Legal and Strategic Implications

  • The scope of the '175 patent's claims provides a competitive moat, particularly if the claims withstand validity challenges.

  • Competitors must design around these claims, perhaps by avoiding specific elements or steps, which may impact product development timelines.

  • Patent strength assessments suggest that while the broad claims are valuable, they could face challenges based on prior art introduced through continued innovation.


Conclusion

The '175 patent encapsulates a strategic IP position in its field, leveraging a combination of broad and specific claims that potentially provide robust protection. Nevertheless, its long-term enforceability hinges on patent validity, challenged by a crowded prior art landscape. The patent's scope and claims demonstrate a deliberate effort to carve out a niche, but continued development and vigilant IP management are essential.


Key Takeaways

  1. Broad Claim Strategy: The '175 patent employs broad independent claims that, if upheld, grant significant control over the technology segment, discouraging competitors.

  2. Vulnerability to Prior Art: The claims' novelty may be challenged by existing art; an ongoing watch on prior filings is essential.

  3. Innovation Clusters: A dense patent environment indicates high competitive activity, necessitating strategic IP positioning.

  4. Potential for Litigation: Overlapping rights with patents from competitors could lead to litigation or cross-licensing negotiations, affecting commercialization.

  5. Forward-Looking IP Management: Continuous innovation and meticulous claim drafting remain vital to maintain patent sovereignty and market advantage.


FAQs

1. What is the core innovation claimed in the '175 patent?
The core claims focus on [specific process, compound, device, or method], characterized by [key features], aimed at [main benefit or problem addressed].

2. How strong are the '175 patent's claims against competitors?
The claims are strategically broad, offering substantial protection. However, their strength depends on validity against prior art and potential infringement challenges.

3. Can the claims be easily avoided?
Potentially. Competitors may circumvent by modifying features not explicitly protected by the claims, especially if claims are narrowly interpreted or if alternative inventive solutions exist.

4. What is the significance of the patent landscape surrounding the '175 patent?
A saturated IP environment increases the risk of infringement or invalidation, underscoring the need for careful IP strategy and continuous innovation.

5. Is there a risk of patent infringement if competitors develop similar technologies?
Yes. The broad scope of the claims, if valid, could lead to infringement litigation unless alternative designs avoid the patented elements.


References

[1] United States Patent and Trademark Office. Patent 10,087,175.
[2] Prior art references and mappings in publicly available patent databases (e.g., USPTO, EPO).
[3] Analysis reports on patent landscapes in the relevant technological domain.

More… ↓

⤷  Get Started Free

Details for Patent 10,087,175

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 10,087,175 2035-04-01
Amgen Inc. NEUPOGEN filgrastim Injection 103353 February 20, 1991 10,087,175 2035-04-01
Amgen Inc. NEUPOGEN filgrastim Injection 103353 June 28, 2000 10,087,175 2035-04-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.